<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="231212">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068250</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG-0227</org_study_id>
    <secondary_id>CDR0000301563</secondary_id>
    <nct_id>NCT00068250</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma</brief_title>
  <official_title>Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radiation Therapy Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>NRG Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radiation Therapy Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy such as methotrexate and temozolomide use different
      ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies
      such as rituximab can locate cancer cells and either kill them or deliver cancer-killing
      substances to them without harming normal cells. Radiation therapy uses high-energy x-rays
      to damage cancer cells. Combining methotrexate, temozolomide, and rituximab with radiation
      therapy may kill more cancer cells.

      PURPOSE: This phase I/II trial is studying the side effects and best dose of temozolomide
      when given together with methotrexate and rituximab followed by radiation therapy and to see
      how well they work in treating patients with primary central nervous system lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the maximum tolerated dose of temozolomide in combination with methotrexate
           and rituximab before fractionated whole brain radiotherapy in patients with primary
           central nervous system lymphoma.

        -  Compare the 2-year survival rate of patients receiving this chemotherapy regimen before
           radiotherapy and temozolomide after radiotherapy to that of patients treated on
           protocol RTOG-9310.

        -  Compare the tumor response rates of patients treated with this chemotherapy regimen
           before radiotherapy to that of patients treated on Radiation Therapy Oncology Group
           (RTOG), RTOG-9310.

        -  Determine the progression-free survival of patients treated with this regimen.

        -  Determine the acute and long-term neurologic toxicity of this regimen in these
           patients.

        -  Determine the quality of life of patients treated with this regimen.

      OUTLINE: This is a phase I dose-escalation study of temozolomide in combination with
      methotrexate and rituximab before radiotherapy, followed by a phase II study.

      Phase I

        -  Pre-radiotherapy chemotherapy: Patients receive rituximab IV 3 days prior to the first
           course of methotrexate. Patients then receive methotrexate IV over 4 hours on weeks 1,
           3, 5, 7, and 9 (for a total of 5 doses). Patients also receive oral temozolomide daily
           for 5 days on weeks 4 and 8.

      Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated
      dose (MTD) is determined. The MTD is defined as the dose at which no more than 0 of 3 or 1
      of 6 patients experience dose-limiting toxicity.

        -  Radiotherapy: Patients undergo whole brain radiotherapy daily for 5 days on weeks 11,
           12, and 13.

        -  Post-radiotherapy chemotherapy: Patients receive oral temozolomide once daily on days
           1-5 beginning at week 14. Treatment repeats every 28 days for 10 courses in the absence
           of unacceptable toxicity.

      Phase II

        -  Patients receive treatment as in phase I at the MTD of temozolomide. Treatment
           continues in the absence of unacceptable toxicity.

      Quality of life is assessed at baseline, at weeks 10 and 13, every 2 months during
      post-radiotherapy temozolomide therapy, at the end of therapy, every 3 months for 2 years,
      every 6 months for 3 years, and then annually thereafter.

      Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then
      annually thereafter.

      PROJECTED ACCRUAL: A total of 52-64 patients (up to 18 patients for phase I and 46 patients
      for phase II) will be accrued for this study within 19 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity rate (Phase I)</measure>
    <time_frame>From start of treatment to 10 weeks.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival rate at 2 years (Phase ll)</measure>
    <time_frame>Death or last follow-up. Anaylsis occurs after all patients have been potentially followed for 2 years.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-irradiation chemotherapy tumor response rate (Phase II)</measure>
    <time_frame>From start of treatment to 10 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (Phase II)</measure>
    <time_frame>From randomization to date of progression, death or last follow-up. Analysis occurs at the same time as the primary outcome analysis.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase I: Temozolomide (TMZ) 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Temozolomide 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Temozolomide (TMZ) 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Temozolomide 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I: Temozolomide (TMZ) 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I: Temozolomide 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II: Temozolomide (TMZ) 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II: Temozolomide 100 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <arm_group_label>Phase I: Temozolomide (TMZ) 100mg</arm_group_label>
    <arm_group_label>Phase I: Temozolomide (TMZ) 150 mg</arm_group_label>
    <arm_group_label>Phase I: Temozolomide (TMZ) 200 mg</arm_group_label>
    <arm_group_label>Phase II: Temozolomide (TMZ) 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>Phase I: Temozolomide (TMZ) 100mg</arm_group_label>
    <arm_group_label>Phase I: Temozolomide (TMZ) 150 mg</arm_group_label>
    <arm_group_label>Phase I: Temozolomide (TMZ) 200 mg</arm_group_label>
    <arm_group_label>Phase II: Temozolomide (TMZ) 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temozolomide</intervention_name>
    <arm_group_label>Phase I: Temozolomide (TMZ) 100mg</arm_group_label>
    <arm_group_label>Phase I: Temozolomide (TMZ) 150 mg</arm_group_label>
    <arm_group_label>Phase I: Temozolomide (TMZ) 200 mg</arm_group_label>
    <arm_group_label>Phase II: Temozolomide (TMZ) 100 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <arm_group_label>Phase I: Temozolomide (TMZ) 100mg</arm_group_label>
    <arm_group_label>Phase I: Temozolomide (TMZ) 150 mg</arm_group_label>
    <arm_group_label>Phase I: Temozolomide (TMZ) 200 mg</arm_group_label>
    <arm_group_label>Phase II: Temozolomide (TMZ) 100 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Cytologically confirmed primary central nervous system (CNS) lymphoma

               -  Based on positive biopsy, cerebrospinal fluid, or vitreous cytology (in
                  association with measurable intraparenchymal tumor)

               -  B-cell type

               -  Cluster of Differentiation antigen (CD20)+ disease

               -  Cytology must demonstrate lymphoma OR an immunohistochemical diagnosis of
                  malignant lymphocytes with a monoclonal lymphocytic population

          -  No evidence of systemic lymphoma

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-2

        Life expectancy

          -  At least 8 weeks

        Hematopoietic

          -  Absolute granulocyte count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than 2 times upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) no greater than 2 times ULN

          -  Alkaline phosphatase no greater than 2 times ULN

          -  No active hepatitis B

        Renal

          -  Creatinine clearance at least 50 mL/min

          -  No renal insufficiency

        Other

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No HIV positivity

          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or
             carcinoma in situ of the cervix

          -  No history of idiopathic sensitivity to any of the drugs in this study

          -  No active infection

          -  No known anaphylaxis or Immunoglobulin E (IgE)-mediated hypersensitivity to murine
             proteins or to any component of rituximab

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy to the brain, head, or neck

        Surgery

          -  No prior organ transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Glass, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Cancer Center at Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Integrated Community Oncology Network</name>
      <address>
        <city>Jacksonville Beach</city>
        <state>Florida</state>
        <zip>32250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cancer Institute - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network at Southside Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Medical Center South</name>
      <address>
        <city>Jascksonville</city>
        <state>Florida</state>
        <zip>32258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrated Community Oncology Network - Orange Park</name>
      <address>
        <city>Orange Park</city>
        <state>Florida</state>
        <zip>32073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Center - Palatka</name>
      <address>
        <city>Palatka</city>
        <state>Florida</state>
        <zip>32177</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flagler Cancer Center</name>
      <address>
        <city>Saint Augustine</city>
        <state>Florida</state>
        <zip>32086</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Nevada Cancer Research Foundation</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John F. Kennedy Medical Center</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Milwaukie Hospital</name>
      <address>
        <city>Milwaukie</city>
        <state>Oregon</state>
        <zip>97222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center at Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213-2967</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Columbia River Oncology Program</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence St. Vincent Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kimmel Cancer Center at Thomas Jefferson University - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107-5541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center at Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jon and Karen Huntsman Cancer Center at Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Valley Regional Medical Center - Provo</name>
      <address>
        <city>Provo</city>
        <state>Utah</state>
        <zip>84604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Washington Medical Center Cancer Center</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Memorial Hospital Cancer Care Center</name>
      <address>
        <city>Menomonee Falls</city>
        <state>Wisconsin</state>
        <zip>53051</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 30, 2016</lastchanged_date>
  <firstreceived_date>September 10, 2003</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>primary central nervous system Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
